share_log

LevelJump Healthcare Corp. Reports Third Quarter 2023 Results

LevelJump Healthcare Corp. Reports Third Quarter 2023 Results

LevelJump 醫療保健公司公佈2023年第三季度業績
newsfile ·  2023/11/29 21:28

Toronto, Ontario--(Newsfile Corp. - November 29, 2023) - LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("LevelJump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce today it has reported financial results for the third fiscal quarter ended September 30, 2023. All amounts are expressed in Canadian dollars.

加拿大安大略省多倫多--(Newsfile Corp.,2023年11月29日)——加拿大B2B遠程醫療解決方案領域的領導者LevelJump Healthcare Corp.(多倫多證券交易所股票代碼:JUMP)(場外交易代碼:JMPHF)(FSE:75J)(“LevelJump” 或 “公司”)今天欣然宣佈,它已公佈截至2023年9月30日的第三財季的財務業績。所有金額均以加元表示。

Financial and Operational Highlights

財務和運營要點

  • Revenues from operations were $2,856,044 for the third quarter, an increase of 31% from the prior year.

  • Gross profits from operations were $739,479 for the third quarter, an increase of 14% from the prior year.

  • 第三季度的運營收入爲2856,044美元,比上年增長31%。

  • 第三季度的運營總利潤爲739,479美元,比上年增長14%。

"Despite a challenging market and economic landscape, we progressed on our organic growth and our acquisition plan as well as expanded our teleradiology services to Saskatchewan, solidifying JUMP as a national provider," said Mitch Geisler, CEO. "Looking ahead, our immediate priority is to sustain revenue growth by leveraging both our recently acquired and established Diagnostic Centers while consistently delivering value to our shareholders."

首席執行官米奇·蓋斯勒說:“儘管市場和經濟格局充滿挑戰,但我們在有機增長和收購計劃方面取得了進展,並將遠程放射學服務擴展到了薩斯喀徹溫省,鞏固了JUMP作爲全國提供商的地位。”“展望未來,我們的當務之急是通過利用我們最近收購和建立的診斷中心來維持收入增長,同時持續爲股東創造價值。”

Non-IFRS Financial Measures

非國際財務報告準則財務指標

This news release contains financial terms (such as adjusted EBITDA) that are not considered in IFRS. Such financial measures, together with measures prepared in accordance with IFRS, provide useful information to investors and shareholders, as management uses them to evaluate the operating performance of the Company. The Company's determination of these non-IFRS measures may differ from other reporting issuers, and therefore are unlikely to be comparable to similar measures presented by other companies. Further, these non-IFRS measures should not be considered in isolation or as a substitute for measures of performance or cash flows prepared in accordance with IFRS. These financial measures are included because management uses this information to analyze operating performance and liquidity.

本新聞稿包含國際財務報告準則中未考慮的財務條款(例如調整後的息稅折舊攤銷前利潤)。此類財務指標加上根據國際財務報告準則制定的衡量標準,爲投資者和股東提供了有用的信息,因爲管理層使用它們來評估公司的經營業績。公司對這些非國際財務報告準則指標的確定可能與其他申報發行人不同,因此不太可能與其他公司提出的類似指標相提並論。此外,不應孤立地考慮這些非《國際財務報告準則》衡量標準,也不能替代按照《國際財務報告準則》編制的業績或現金流衡量標準。之所以包括這些財務指標,是因爲管理層使用這些信息來分析經營業績和流動性。

Adjusted EBITDA & Annual Revenue Run Rate

調整後的息稅折舊攤銷前利潤和年收入運行率

Management believes adjusted EBITDA is a useful supplemental measure to determine the Company's ability to generate cash available for working capital, capital expenditures, debt repayments, interest expense and income taxes.

管理層認爲,調整後的息稅折舊攤銷前利潤是確定公司爲營運資金、資本支出、債務償還、利息支出和所得稅產生可用現金的有用補充衡量標準。

EBITDA refers to net income (loss) determined in accordance with IFRS, before depreciation and amortization, net interest expense (income), income tax expense (recovery) and extraordinary items. The Company defines adjusted EBITDA as EBITDA, plus stock-based compensation expense, restructuring, fair value adjustments, listing expense and transaction costs, impairment, and finance income.

息稅折舊攤銷前利潤是指根據國際財務報告準則確定的折舊和攤銷前的淨收益(虧損)、淨利息支出(收入)、所得稅支出(回收)和特殊項目。公司將調整後的息稅折舊攤銷前利潤定義爲息稅折舊攤銷前利潤,加上股票薪酬支出、重組、公允價值調整、上市費用和交易成本、減值和財務收益。

A reconciliation of adjusted EBITDA to net income (loss) is as follows.

調整後的息稅折舊攤銷前利潤與淨收益(虧損)的對賬情況如下。


3 Months ended
September 30, 2023
3 Months ended
September 30, 2022
9 Months ended
September 30, 2023
9 Months ended
September 30, 2023





Revenues 2,856,044 2,296,187 9,015,126 6,611,990
Cost of Sales 2,116,565

1,649,041

6,400,165

4,818,527
Gross Profit
739,479

647,146

2,614,962

1,793,463
Operating Expenses 947,065 813,637 3,180,811 2,499,092
Net Profit (207,586) (166,491) (565,850) (705,629)
Other Income - 188 116,604 102,958
Other Expenses 1,386,054

43,315

1,579,627

134,545
Net Income/(Loss)
(1,593,641)
(209,618)
(2,028,873)
(737,216)
add back
Finance costs 59,411 40,219 176,587 100,358
Amortization and Depreciation 129,059

51,335

341,251

145,368
EBITDA
(1,405,171)
(118,064)
(1,511,034)
(491,490)
add back
Stock Based compensation - 36,833 - 256,499
Broker Commissions - - 66,500 20,201
Investment losses 1,329,876 - 1,329,876 2,971
Other (3,232) 3,096 6,664 11,015
One time nonrecurring operating expenses 100,000 100,000 100,000 100,000
subtract other Income -

188

116,604

102,958
Adjusted EBITDA
21,473

21,677

(124,598)
(203,762)

3 個月已結束
2023年9月30日
3 個月已結束
2022年9月30日
9 個月已結束
2023年9月30日
9 個月已結束
2023年9月30日





收入 2,856,044 2,296,187 9,015,126 6,611,990
銷售成本 2,116,565

1,649,041

6,400,165

4,818,527
毛利
739,479

647,146

2,614,962

1,793,463
運營費用 947,065 813,637 3,180,811 2,499,092
淨利潤 (207,586) (166,491) (565,850) (705,629)
其他收入 - 188 116,604 102,958
其他開支 1,386,054

43,315

1,579,627

134,545
淨收益/(虧損)
(1,593,641)
(209,618)
(2,028,873)
(737,216)
再加回來
財務成本 59,411 40,219 176,587 100,358
攤銷和折舊 129,059

51,335

341,251

145,368
EBITDA
(1,405,171)
(118,064)
(1,511,034)
(491,490)
再加回來
股票薪酬 - 36,833 - 256,499
經紀人佣金 - - 66,500 20,201
投資損失 1,329,876 - 1,329,876 2,971
其他 (3,232) 3,096 6,664 11,015
一次性非經常性運營費用 10萬 10萬 10萬 10萬
減去其他收入 -

188

116,604

102,958
調整後 EBITDA
21,473

21,677

(124,598)
(203,762)

About LevelJump Healthcare

關於 LevelJump

LevelJump Healthcare Corp., (TSXV: JUMP) provides telehealth solutions to client hospitals and imaging centers through its Teleradiology division, as well as in person radiology services through its IHF's (Independent Healthcare Facilities). JUMP focuses primarily on critical care for urgent and emergency patients, establishing integral relationships in the communities we serve.

LevelJump Healthcare Corp.(多倫多證券交易所股票代碼:JUMP)通過其遠程放射學部門爲客戶醫院和成像中心提供遠程醫療解決方案,並通過其IHF(獨立醫療機構)提供面對面放射學服務。JUMP主要專注於緊急和急診患者的重症監護,在我們所服務的社區中建立不可或缺的關係。

ON BEHALF OF THE BOARD OF DIRECTORS OF
LEVELJUMP HEALTHCARE CORP.

代表董事會
LEVELJUMP 醫療保健公司

Mitchell Geisler
Chief Executive Officer

米切爾·蓋斯勒
首席執行官

Caitlin-Robyn Densmore
Investor Relations Manager
Caitlin.Densmore@leveljumphealthcare.com
(437) 214-1568

Caitlin-Robyn Densmore
投資者關係經理
Caitlin.Densmore@leveljumphealthcare.com
(437) 214-1568

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

關於前瞻性信息的警示性聲明

This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business plans and the outlook of the Company's industry. Although the Company believes, in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements in this press release are made as of the date of this release and the Company assumes no responsibility to update them or revise them to reflect new events or circumstances other than as required by applicable securities laws. The Company undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of the Company, Canadian Teleradiology Services, Inc., their securities, or their respective financial or operating results (as applicable).

本新聞稿包含與公司業務計劃和公司行業前景有關的適用證券法所指的 “前瞻性信息”。儘管根據其高管和董事的經驗、當前狀況和預期的未來發展以及其他被認爲適當的因素,公司認爲,這些前瞻性信息中反映的預期是合理的,但不應過度依賴這些期望,因爲公司無法保證這些預期會被證明是正確的。實際結果和發展可能與這些陳述所設想的結果和進展存在重大差異。本新聞稿中的聲明自本新聞稿發佈之日起作出,除適用的證券法要求外,公司不承擔任何責任對其進行更新或修改以反映新的事件或情況。公司沒有義務評論第三方對公司、Canadian Teleradiology Services, Inc.、其證券或各自的財務或經營業績(如適用)的分析、預期或聲明。

Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

交易所及其監管服務提供商(該術語在聯交所政策中定義)均不對本新聞稿的充分性或準確性承擔責任。

The securities being offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor in any other jurisdiction.

所發行的證券過去和將來都不會根據經修訂的1933年《美國證券法》(“美國證券法”)或任何美國州證券法進行註冊,也不得在美國發行或出售,也不得向沒有註冊或未獲得《美國證券法》和適用的美國州證券法註冊要求的適用豁免的美國人發行或出售。本新聞稿不構成在美國或其他任何司法管轄區出售證券的要約或要約購買證券。

To view the source version of this press release, please visit

要查看本新聞稿的源版本,請訪問

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論